QualityStocks would like to highlight Nanosphere, Inc. (NASDAQ: NSPH). The company develops, manufactures, and markets an advanced molecular diagnostic platform, the Verigene System, which enables simple, cost-effective, and highly sensitive nucleic acid (DNA and RNA) and protein testing on a single platform. Their breakthrough technology helps hospitals improve patient care and lowers costs by providing time-critical information, allowing earlier detection of disease and more targeted treatment.
In the company’s news yesterday,
Nanosphere announced that the U.S. Food and Drug Administration has granted 510(k) clearance, permitting the marketing of the company’s CYP2C19 Nucleic Acid Test on the automated sample-to-result Verigene System.
The Verigene CYP2C19 Test is indicated as an aid to help clinicians determine therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. In less than 2.5 hours, the Verigene CYP2C19 Test identifies the CYP2C19 *2, *3, and *17 variations, if present, directly from a patient’s whole blood sample. The test gives physicians the crucial information they need to treat patients quickly and appropriately with the most effective drugs.
The achievement of receiving FDA clearance adds to Nanosphere’s growing array of FDA-cleared assays, which includes tests for gram positive bloodstream infections (BC-GP), respiratory viruses (RV+), hypercoagulation, and warfarin metabolism.
A molecular diagnostics platform with the capability of performing tests for genetic, infectious diseases, and protein targets on a single sample-to-result platform, the Verigene System’s ease of use and on-demand processing capability allow hospitals to generate time-critical results in a near-patient setting.
The CYP2C19 Test received CE IVD Mark in April 2011 for commercial distribution in Europe and all countries recognizing the CE Mark.
Based in Northbrook, Ill., Nanosphere is a developer, manufacturer, and marketer of the Verigene System, an advanced molecular diagnostics platform for detecting life-threatening infections and cardiovascular diseases. Easy to use and cost-effective, the platform allows simple, low-cost, and highly sensitive genomic and protein testing on a single platform.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
